Integration of PPAR Agonists in Treatment Landscape of PBC

Author(s):

Nancy Reau, MD,John Vierling, MD, FACP, FAASLD, AGAF

Key Takeaways

PBC involves autoimmune-mediated destruction of intrahepatic bile ducts by autoreactive T lymphocytes, leading to cholestasis.
Accumulation of toxic bile acids due to cholestasis causes hepatocellular damage and inflammation.
Chronic inflammation from bile duct destruction results in fibrosis and cirrhosis over time.
Genetic predispositions and environmental factors play significant roles in the etiology and progression of PBC.

The panel of experts explore the potential integration of peroxisome proliferator-activated receptor (PPAR) agonists into the current treatment landscape for primary biliary cholangitis (PBC) and provides recommendations for patients currently taking fibrates for managing the disease.

EP: 1.Pathophysiology of PBC

EP: 2.Presentation and Diagnosis of PBC

EP: 3.Differential Diagnosis of PBC

EP: 4.Disease Progression and Extrahepatic Manifestations of PBC

EP: 5.Second-Line Treatments and Management of Symptoms in PBC

EP: 6.Treatment Goals and First-Line Therapy in PBC

EP: 7.Seladelpar for Treatment of PBC

EP: 8.PPAR Agonists for Treatment of PBC

EP: 9.Elafibranor and Choosing Amongst PPAR Agonists in PBC

EP: 10.Pruritus Control With PPAR Agonists in PBC

Now Viewing

EP: 11.Integration of PPAR Agonists in Treatment Landscape of PBC

EP: 12.Treatment Response to PPAR Agonists and Other Therapies in PBC

EP: 13.Thoughts on the Current State of PBC Management

EP: 14.Outcomes and Adoption of PPAR Agonists in PBC

Video content above is prompted by the following:

How do you envision the uptake and integration of PPAR agonists into the current treatment landscape for PBC? What would you recommend for someone who is taking a fibrate for PBC?